WuXi PharmaTech will pay $151 million to acquire privately held AppTec Laboratory Services of St. Paul, Minn. Like WuXi, AppTec is involved in contract research outsourcing. But, while WuXi concentrates on pre-clinical chemistry services, AppTech provides testing, biologics cGMP manufacturing and contract R&D to the biopharma and medical device sectors.  In 2007, AppTec produced just over $70 million of revenue, representing a compounded growth rate of 46% over the past three years. WuXi predicts its 2007 revenues will approach $135 million. More details... 

Stock Symbols: (NYSE: WX) (NYSE: DNA)